Using Biosen to Improve D-Allulose Biosynthesis through Growth-Coupled Evolutionary Pressure on Epimerases

The bottleneck in allulose enzyme development

If you formulate allulose or buy enzymes for rare-sugar production, you know the problem. The main enzymatic route starts with D-fructose and uses a ketose 3-epimerase (KEase) to make D-allulose. Native KEases often lack enough activity or heat stability. Directed evolution can fix that, but only if you can find the rare improved variant among thousands of clones. The authors of this paper built a screening system that makes cells do the sorting for them.

Background

D-allulose is a rare sugar. Manufacturers make it from D-fructose using epimerases. The enzyme's activity and stability determine process efficiency. A more active enzyme cuts enzyme loading. A more stable enzyme extends reaction time or allows higher temperatures. That is why enzyme engineers keep looking for better KEase variants.

Traditional screening methods are slow. They also limit how many mutants you can test. The team behind this paper wanted a high-throughput alternative. They turned to a D-allulose-dependent biosensor called Biosen.

What the study did

The researchers developed a growth-coupled in vivo screening platform. The concept is straightforward. A KEase variant inside a living cell converts fructose to allulose. The biosensor detects that allulose and activates a growth-related signal. More allulose means faster growth. Less allulose means slower growth. Over successive rounds, the population enriches with cells carrying better epimerase genes.

This is not just another analytical screen. It couples enzyme performance to cell survival. That changes evolution pressure. The better the enzyme, the better the cell competes. The authors used this platform to evolve the ketose 3-epimerase ADAE. They isolated a mutant called M42.

Key findings

M42 outperformed the parent enzyme on two fronts that matter in production. Catalytic activity jumped 6.28-fold. Thermostability also improved. At 60°C, the mutant's half-life was 2.5 times longer than the parent's. In a practical conversion test, M42 converted 32.2% of D-fructose to D-allulose within 3 hours.

Metric	M42 result
Catalytic activity	6.28-fold higher than parent
Half-life at 60°C	2.5-fold longer than parent
D-Fructose to D-allulose conversion	32.2% in 3 hours

The activity gain is large. The stability gain is just as valuable. Higher stability gives manufacturers more flexibility with temperature, substrate concentration, and enzyme reuse. The conversion number shows the mutant works under real reaction conditions, not just in an idealized assay.

What it means for manufacturers

For ingredient buyers and formulators, the main point is that allulose enzymes are still getting better. The screening method itself may matter more than this one mutant. Because the system is growth-coupled, it cuts down the need to pick and test individual colonies by hand. That makes directed evolution faster and less expensive.

A biosensor-driven platform also lets you evolve enzymes for specific process constraints. Want an epimerase that works at higher fructose loading? Run the selection under those conditions. Need better stability at elevated temperature? Add that pressure. You can adapt the system not just for ADAE but for other KEases.

From a procurement standpoint, keep an eye on enzyme suppliers using this type of technology. Variants like M42 may not be commercial yet, but they point to a clear direction. The next generation of allulose biocatalysts will likely come from growth-coupled screening rather than random mutagenesis and tedious assays.

FAQ

What does growth-coupled screening mean? It means cells that make more allulose grow faster. The biosensor links allulose concentration to a growth advantage, so the selection pressure is automatic. You do not need to sort every clone.

Is this specific to allulose? The sensor in this paper responds to D-allulose. The same design principle can be applied to other rare sugars if you have a suitable biosensor. For now, the published work is about allulose and KEases.

Can M42 be used in production today? The paper reports enzyme performance data, not commercial-scale trials. M42 shows clear gains in activity, stability, and conversion. A manufacturer would still need to run process validation with its own substrate, equipment, and operating conditions.

The field has moved from brute-force screening to smarter selection. Biosen is a good example. It gives enzyme engineers a direct line between catalytic performance and cell growth. That is exactly the kind of tool that turns a good mutant into a commercially relevant one. For anyone who buys or formulates allulose, the message is simple: better enzymes are coming, and they are getting easier to find.